Rezolute Shares Gain on Positive Ersodetug Indicators Despite Failure to Meet Trial Goals

Dow Jones01-08

By Elias Schisgall

Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints.

Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year.

Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance.

"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy," Rezolute said Wednesday.

Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 07, 2026 11:30 ET (16:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601807662?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601807662","market":"us","top_or_hot":-1,"title":"Rezolute Shares Gain on Positive Ersodetug Indicators Despite Failure to Meet Trial Goals","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of  ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints. \n</p>\n<p>\n  Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year. \n</p>\n<p>\n  Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance. \n</p>\n<p>\n  \"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy,\" Rezolute said Wednesday. \n</p>\n<p>\n  Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2026 11:30 ET (16:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rezolute Shares Gain on Positive Ersodetug Indicators Despite Failure to Meet Trial Goals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRezolute Shares Gain on Positive Ersodetug Indicators Despite Failure to Meet Trial Goals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-08 00:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of  ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints. \n</p>\n<p>\n  Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year. \n</p>\n<p>\n  Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance. \n</p>\n<p>\n  \"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy,\" Rezolute said Wednesday. \n</p>\n<p>\n  Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2026 11:30 ET (16:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601807662","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601807662","pubTimestamp":1767803400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of  ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints.Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year.Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance.\"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy,\" Rezolute said Wednesday.Rezolute said it looks forwar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RZLT":"Rezolute, Inc."},"translate_title":"尽管未能实现试验目标，Rezolute股价仍因Ersodetug积极指标而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RZLT":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of  ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints. \n\n\n  Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year. \n\n\n  Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance. \n\n\n  \"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy,\" Rezolute said Wednesday. \n\n\n  Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2026 11:30 ET (16:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601807662","isCrawlerRequest":true}